KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Net Margin (2016 - 2026)

Pacira BioSciences has reported Net Margin over the past 17 years, most recently at 1.64% for Q1 2026.

  • For Q1 2026, Net Margin fell 120.0% year-over-year to 1.64%; the TTM value through Mar 2026 reached 0.7%, up 1546.0%, while the annual FY2025 figure was 0.97%, 1517.0% up from the prior year.
  • Net Margin for Q1 2026 was 1.64% at Pacira BioSciences, up from 0.83% in the prior quarter.
  • Over five years, Net Margin peaked at 15.2% in Q2 2023 and troughed at 85.11% in Q3 2024.
  • A 5-year average of 0.81% and a median of 3.03% in 2025 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: plummeted -9173bps in 2024 and later surged 8813bps in 2025.
  • Year by year, Net Margin stood at 2.11% in 2022, then skyrocketed by 551bps to 13.72% in 2023, then tumbled by -38bps to 8.57% in 2024, then plummeted by -90bps to 0.83% in 2025, then surged by 98bps to 1.64% in 2026.
  • Business Quant data shows Net Margin for PCRX at 1.64% in Q1 2026, 0.83% in Q4 2025, and 3.03% in Q3 2025.